Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

INTRODUCTION: New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibitor approved by the US Food and Drug Administration, reduces intraocular press...

Descripción completa

Detalles Bibliográficos
Autores principales: Asrani, Sanjay, Bacharach, Jason, Holland, Edward, McKee, Hayley, Sheng, Huan, Lewis, Richard A., Kopczynski, Casey C., Heah, Theresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140751/
https://www.ncbi.nlm.nih.gov/pubmed/32166538
http://dx.doi.org/10.1007/s12325-020-01277-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140751/
https://www.ncbi.nlm.nih.gov/pubmed/32166538
http://dx.doi.org/10.1007/s12325-020-01277-2

Ejemplares similares